ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

TACSTD2

tumor associated calcium signal transducer 2 · also TROP2, GA733-1, EGP-1, M1S1

12 programs in company-led studies act on TACSTD2, from 11 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
sacituzumab govitecanruleGilead Sciences–phase 43020 running–ChEMBL
sacituzumab tirumotecanMerckinhibitorphase 35048 running–a judged reading
datopotamab deruxtecanruleAstraZeneca–phase 32928 running–NCIt
JSKN016ruleAlphamab Oncology–phase 355 runningERBB3the studies' text
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceutical–phase 332 running–NCIt
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceutical–phase 233 running–NCIt
sacituzumab drozuntecanruleDualityBio–phase 222 running–NCIt
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleAvenzo Therapeutics–phase 211 runningNECTIN4NCIt
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleOBI Pharma–phase 211 running–NCIt
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharma–phase 211 running–NCIt
JSKN016HCruleAlphamab Oncology–phase 111 runningERBB3the studies' text
KH815ruleChengdu Kanghong Pharmaceutical Group–phase 111 running–the studies' text

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.